Yakisich Juan Sebastian, Venkatadri Rajkumar, Azad Neelam, Iyer Anand Krishnan V
Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University, Hampton, Virginia.
J Cell Physiol. 2017 Aug;232(8):2033-2043. doi: 10.1002/jcp.25514. Epub 2017 Feb 28.
The efficacy of chemotherapy is hindered by both tumor heterogeneity and acquired or intrinsic multi-drug resistance caused by the contribution of multidrug resistance proteins and stemness-associated prosurvival markers. Therefore, targeting multi-drug resistant cells would be much more effective against cancer. In this study, we characterized the chemoresistance properties of adherent (anchorage-dependent) lung H460 and breast MCF-7 cancer cells growing under prolonged periods of serum starvation (PPSS). We found that under PPSS, both cell lines were highly resistant to Paclitaxel, Colchicine, Hydroxyurea, Obatoclax, Wortmannin, and LY294002. Levels of several proteins associated with increased stemness such as Sox2, MDR1, ABCG2, and Bcl-2 were found to be elevated in H460 cells but not in MCF-7 cells. While pharmacological inhibition of either MDR1, ABCG2, Bcl-2 with Verapamil, Sorafenib, or Obatoclax, respectively decreased the levels of their target proteins under routine culture conditions as expected, such inhibition did not reverse PX resistance in PPSS conditions. Paradoxically, treatment with inhibitors in serum-starved conditions produced an elevation of their respective target proteins. In addition, we found that Digitoxin, an FDA approved drug that decrease the viability of cancer cells growing under PPSS, downregulates the expression of Sox2, MDR1, phospho- AKT, Wnt5a/b, and β-catenin. Our data suggest that PPSS-induced chemoresistance is the result of extensive rewiring of intracellular signaling networks and that multi-resistance can be effectively overcome by simultaneously targeting multiple targets of the rewired network. Furthermore, our PPSS model provides a simple and useful tool to screen drugs for their ability to target multiple pathways of cancer resistance. J. Cell. Physiol. 232: 2033-2043, 2017. © 2016 Wiley Periodicals, Inc.
肿瘤异质性以及由多药耐药蛋白和干性相关生存促进标志物导致的获得性或内在性多药耐药性,均会阻碍化疗的疗效。因此,靶向多药耐药细胞对癌症治疗可能更有效。在本研究中,我们对长期血清饥饿(PPSS)条件下贴壁生长(锚定依赖)的肺癌H460细胞和乳腺癌MCF - 7细胞的化疗耐药特性进行了表征。我们发现,在PPSS条件下,这两种细胞系对紫杉醇、秋水仙碱、羟基脲、 obatoclax、渥曼青霉素和LY294002均具有高度抗性。我们发现,与干性增加相关的几种蛋白质,如Sox2、MDR1、ABCG2和Bcl - 2,在H460细胞中水平升高,而在MCF - 7细胞中则未升高。虽然在常规培养条件下,分别用维拉帕米、索拉非尼或obatoclax对MDR1、ABCG2、Bcl - 2进行药理抑制,如预期那样降低了其靶蛋白水平,但这种抑制在PPSS条件下并未逆转对紫杉醇的抗性。矛盾的是,在血清饥饿条件下用抑制剂处理会导致其各自靶蛋白水平升高。此外,我们发现洋地黄毒苷,一种FDA批准的可降低PPSS条件下生长的癌细胞活力的药物,可下调Sox2、MDR1、磷酸化AKT、Wnt5a/b和β-连环蛋白的表达。我们的数据表明,PPSS诱导的化疗耐药是细胞内信号网络广泛重排的结果,并且通过同时靶向重排网络的多个靶点可以有效克服多药耐药。此外,我们的PPSS模型提供了一个简单且有用的工具,用于筛选药物靶向癌症耐药多条途径的能力。《细胞生理学杂志》232: 2033 - 2043, 2017。© 2016威利期刊公司